-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
At the end of 2021, the State Food and Drug Administration approved the listing of sugelimab (Zejiemei) for use in combination with pemetrexed and carboplatin for epidermal growth factor receptor (EGFR) gene mutation-negative and anaplastic lymphoma kinase (ALK).
First-line treatment of patients with ALK)-negative metastatic non-squamous non-small cell lung cancer, and combination paclitaxel and carboplatin for the first-line treatment of patients with metastatic squamous non-small cell lung cancer
.
It is reported that this is also the second PD-L1 immunotherapy drug approved for marketing in China
.
Up to now, the number of PD-1/L1 in China has reached 12, including 6 domestic PD-1, 2 imported PD-1, 2 imported PD-L1, and 2 domestic PD-L1
.
In addition, there are a number of PD-(L)1s that are queuing up for approval, such as Henlius’ slulimumab, Jiahe Bio-B’s genusumab, and Lepu Bio’s pretlimumab etc.
_ The advent of immunotherapy has brought new treatment options to the majority of patients.
In China, the price of such drugs is very expensive.
When Bill's imported "K drug" was launched in China, the annual cost was as high as 300,000 yuan.
It's a heavy burden
.
In recent years, as the domestic immunotherapy research and development fever has continued to rise, the news of domestic new drug approvals has continued, and the competition on the track has become more intense.
Price reduction has become the choice of enterprises, including Innovent Bio, BeiGene and many other pharmaceutical companies are actively Strive for the opportunity to enter the medical insurance to obtain a large amount
.
In 2019, Innovent's sintilimab became the first PD-1 product to be included in the National Medical Insurance Catalog with a 64% drop, which means that PD-1 has officially entered the era of 100,000/year
.
From January 1, 2022, the new version of the medical insurance catalog will be officially implemented, and the four domestic PD-1s are all included in the catalog
.
According to relevant industry media reports, many products have been reduced in price
.
For example, sintilimab 10ml/100mg/bottle originally cost 2,843 yuan, and after entering the medical insurance, it was reduced to 1,080 yuan, a decrease of 62%; toripalimab 2ml: 80mg specification was reduced from 906.
08 yuan/vial to 825.
00 yuan/ 6ml: 240mg specification dropped from 2100.
97 yuan/piece to 1912.
96 yuan/piece; BeiGene Tislelizumab 10ml: 100mg dropped from 2180 yuan/piece to 1450 yuan, a price reduction of 33%
.
With the entry of these monoclonal antibody products into the medical insurance catalog, the price will be further reduced, which will greatly reduce the burden of drug costs for patients
.
Not only domestic varieties, but also imported varieties are affected by the impact of domestic varieties, and measures have been taken to reduce the burden on patients
.
For example, in the past, patients using K medicine cost nearly 300,000 yuan per year after charitable assistance.
In 2021, the K medicine patient assistance project released a new plan: From January 1, 2021, patients only need to pay for 4 courses of treatment and cost 140,000 yuan.
You can get full assistance with K medicine
.
O Medicine has also updated the patient assistance project.
The plan announced in 2020 is: from the original "first 3+3, follow-up 3+4 cycle" to the annual "3+3, follow-up 3+X", that is, those that meet the project standards A patient, who pays up to 6 times of Odivo’s treatment costs during the application year, can receive all the drug assistance remaining in the application year.
The patient can repeat the application for assistance according to the application year until the program is terminated or the disease progresses
.
With the release of the new plan, the annual out-of-pocket ratio of patients has dropped by more than 75% compared with the listed price, and the burden of drug expenses has been further reduced
.
The industry predicts that in the case of the crowded PD-1/L1 track, the price reduction of PD-1/L1 products may become a trend in the "ordinary people's homes" in the future, which will be a great boon for the majority of patients
.
First-line treatment of patients with ALK)-negative metastatic non-squamous non-small cell lung cancer, and combination paclitaxel and carboplatin for the first-line treatment of patients with metastatic squamous non-small cell lung cancer
.
It is reported that this is also the second PD-L1 immunotherapy drug approved for marketing in China
.
Up to now, the number of PD-1/L1 in China has reached 12, including 6 domestic PD-1, 2 imported PD-1, 2 imported PD-L1, and 2 domestic PD-L1
.
In addition, there are a number of PD-(L)1s that are queuing up for approval, such as Henlius’ slulimumab, Jiahe Bio-B’s genusumab, and Lepu Bio’s pretlimumab etc.
_ The advent of immunotherapy has brought new treatment options to the majority of patients.
In China, the price of such drugs is very expensive.
When Bill's imported "K drug" was launched in China, the annual cost was as high as 300,000 yuan.
It's a heavy burden
.
In recent years, as the domestic immunotherapy research and development fever has continued to rise, the news of domestic new drug approvals has continued, and the competition on the track has become more intense.
Price reduction has become the choice of enterprises, including Innovent Bio, BeiGene and many other pharmaceutical companies are actively Strive for the opportunity to enter the medical insurance to obtain a large amount
.
In 2019, Innovent's sintilimab became the first PD-1 product to be included in the National Medical Insurance Catalog with a 64% drop, which means that PD-1 has officially entered the era of 100,000/year
.
From January 1, 2022, the new version of the medical insurance catalog will be officially implemented, and the four domestic PD-1s are all included in the catalog
.
According to relevant industry media reports, many products have been reduced in price
.
For example, sintilimab 10ml/100mg/bottle originally cost 2,843 yuan, and after entering the medical insurance, it was reduced to 1,080 yuan, a decrease of 62%; toripalimab 2ml: 80mg specification was reduced from 906.
08 yuan/vial to 825.
00 yuan/ 6ml: 240mg specification dropped from 2100.
97 yuan/piece to 1912.
96 yuan/piece; BeiGene Tislelizumab 10ml: 100mg dropped from 2180 yuan/piece to 1450 yuan, a price reduction of 33%
.
With the entry of these monoclonal antibody products into the medical insurance catalog, the price will be further reduced, which will greatly reduce the burden of drug costs for patients
.
Not only domestic varieties, but also imported varieties are affected by the impact of domestic varieties, and measures have been taken to reduce the burden on patients
.
For example, in the past, patients using K medicine cost nearly 300,000 yuan per year after charitable assistance.
In 2021, the K medicine patient assistance project released a new plan: From January 1, 2021, patients only need to pay for 4 courses of treatment and cost 140,000 yuan.
You can get full assistance with K medicine
.
O Medicine has also updated the patient assistance project.
The plan announced in 2020 is: from the original "first 3+3, follow-up 3+4 cycle" to the annual "3+3, follow-up 3+X", that is, those that meet the project standards A patient, who pays up to 6 times of Odivo’s treatment costs during the application year, can receive all the drug assistance remaining in the application year.
The patient can repeat the application for assistance according to the application year until the program is terminated or the disease progresses
.
With the release of the new plan, the annual out-of-pocket ratio of patients has dropped by more than 75% compared with the listed price, and the burden of drug expenses has been further reduced
.
The industry predicts that in the case of the crowded PD-1/L1 track, the price reduction of PD-1/L1 products may become a trend in the "ordinary people's homes" in the future, which will be a great boon for the majority of patients
.
